Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.
New Guidance Proposed for Ultrasound Use in RA
In a session on a current ACR project on musculoskeletal ultrasound (MSUS), Gurjit Kaeley, MBBS, RhMSUS, MRCP, division chief, professor of medicine, fellowship program director and program director for musculoskeletal ultrasound at the University of Florida College of Medicine, Jacksonville, will present information on proposed guidance related to rheumatoid arthritis. The ACR places a high…
An Expert’s Take on the Best Research in RA to Be Presented at ACR Convergence 2024
With thousands of research abstracts and posters being presented at ACR Convergence 2024, Nov. 14–19, at the Walter E. Washington Convention Center in Washington, D.C., figuring out which research is important today, which could prove important in the future, what has the potential to affect clinical care or prove the basis for future research is…
Updates in RA-Associated ILD
On Sunday, Nov. 17, at ACR Convergence 2024, three speakers will deliver a presentation on Rheumatoid Arthritis-Associated Interstitial Lung Disease: Advances in Screening, Diagnosis and Patient Phenotyping. This session will have three 20-minute presentations that cover distinct aspects of RA-associated ILD from early identification of ILD through high-resolution computed tomography (HRCT) text mining, to phenotyping…
Challenging Cases in Rheumatoid Arthritis
As part of the Review Course on Friday Nov. 15 at ACR Convergence 2024, Iain McInnes, MD, will present a session on Challenging Cases in Rheumatoid Arthritis. Case reports represent a healthcare encounter involving a real person with a real clinical problem. They encourage discussions of real-world concerns and experiences, supporting knowledge acquisition and enhancing…
The Impact of Climate Change
Although research is still emerging, evidence suggests changes in climate, such as increases in heat, pollution and allergens, may increase the risk of flare and hospitalization in patients with rheumatoid arthritis, systemic lupus erythematosus and other rheumatic conditions. Paul Dellaripa, MD, discussed the research and how rheumatologists can help their patients.
Tofacitinib Increases Risk of Venous Thromboembolism
Background & Objectives The ORAL Surveillance trial (NCT02092467), a postauthorization safety study of tofacitinib in patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor, found a dose-dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events when patients were treated with tofacitinib vs. a tumor…
The ACR and CHEST Release 2 New ILD Guidelines
Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).
FDA Approves Tocilizumab Biosimilar; Plus New Lupus Drug in Early Trials
The FDA has approved tocilizumab-aazg (Tyenne), the first tocilizumab biosimilar, for treating rheumatic diseases, as well as the new drug application for CB-101, a chimeric antigen receptor T cell therapy, for treating lupus nephritis and extra-renal lupus.
The Prospect of Rheumatoid Arthritis Prevention
Rheumatoid arthritis (RA) is treatable, and for that, we should be grateful. But wouldn’t it be better if we could prevent it from even happening? Recent data from a study in China demonstrated some interesting results. Could an older type of diabetes medication be the answer we’ve been looking for? Background Preclinical studies have suggested…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 75
- Next Page »